Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cedars-Sinai, global consortium develop stem cell tool to test Huntington’s treatments

06.07.2012
From skin cells to brain cells, new “disease in a dish” model offers step forward in understanding fatal inherited disorder and ways to test therapies for it

Cedars-Sinai scientists, in collaboration with expert colleagues around the globe, used stem cells to re-create Huntington’s Disease in a petri dish, allowing researchers for the first time to test potential treatments for the fatal inherited neurological disorder directly on human cells.

As outlined in a paper published online by Cell Stem Cell and slated for print in the journal’s Aug. 3 issue, scientists at Cedars-Sinai’s Regenerative Medicine Institute and the University of Wisconsin took skin cells from patients with Huntington’s disease and reprogrammed them into powerful stem cells; these were then made into the nervous system cells affected by the disease. Seven laboratories around the world collaborated to demonstrate the cells had hallmarks of Huntington’s.

“Now that we’ve moved from skin cells to brain cells, the next step forward will be to test treatments we can move from the petri dish to the clinic,” said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute and a senior author of the study. “In addition to increasing our understanding of this disorder and offering a new pathway to identifying treatments, this study is remarkable because of the extensive interactions between a large group of scientists focused on developing this model. It’s a new way of doing trailblazing science.”

This breakthrough is the latest example of an innovative use for stem cells, reprogramming them to create laboratory versions of diseases. This method has been used to mimic Parkinson’s disease, Alzheimer’s disease, ALS and spinal muscular atrophy. As these diseases all occur in living neurons – that patients can’t part with – the disease-in-a-dish models offer scientists an opportunity they never had before: to study in human cells how a disease attacks the neurons and plot strategies for fighting it.

The Huntington’s Disease iPSC Consortium united some of the world’s top scientists working on this disease. Cedars-Sinai researchers took skin cells from a several Huntington’s patients, including a six-year-old with a severe juvenile form of the disease. They genetically reprogrammed these tissues into induced pluripotent stem cells, which can be made into any type of cell in the body. The cells lines were banked by scientists at Cedars-Sinai and scrutinized by all consortium members for differences that may have led to the disease. These cell lines are now an important resource for Huntington’s researchers and have been made available via a National Institutes of Health-funded repository at Coriell Institute for Medical Research in New Jersey.

Huntington’s, known to the public, for example, as the cause of folksinger Woody Guthrie’s death, typically strikes patients in midlife. It causes jerky, twitching motions, loss of muscle control, psychiatric disorders and dementia; the disease ultimately is fatal. In rare, severe cases, the disorder appears in childhood.

Researchers believe that Huntington’s results from a mutation in the huntintin gene, leading to production of an abnormal protein and ultimately cell death in specific areas of the brain that control movement and cognition. There is no cure for Huntington’s, nor therapies to slow its progression.

The consortium showed Huntington’s cell deficits or how they differ from normal cells, including that they were less likely to survive cultivation in the petri dish. Scientists tried depriving them of a growth factor present around normal cells, or “stressing” them, and found that Huntington’s neurons died even faster. The trick with disease-in-a-dish models is verifying that the cells are, in fact, behaving in the same manner they would in a patient, said Virginia Mattis, a post-doctoral scientist at the Cedars-Sinai Regenerative Medicine Institute and one of the lead authors of the study.

“It was great that these characteristics were seen not only in our laboratory, but by all of the consortium members using different techniques,” Mattis said. “It was very reassuring and significantly strengthens the value of this study.”

This new model will provide the foundation for a new round of experiments by the consortium funded by a new grant from the NIH and the California Institute for Regenerative Medicine.

The Cedars-Sinai’s Regenerative Medicine Institute has made a major commitment to projects like this Huntington’s study in which stem cell research helps to advance understanding of human disease and open new and innovative methods to identify treatments and cures. The institute has developed an induced pluripotent stem cell core facility and recruited faculty to work in this emerging area of regenerative medicine research.

“At last, we have a human cell model for this tragic disease that will be a powerful new tool in identifying treatments for these patients,” said Shlomo Melmed, MD, dean of the medical faculty at Cedars-Sinai and the Helena A. and Philip E. Hixon Chair in Investigative Medicine. “This development is a compelling example of how important iPS cells are to furthering our understanding and finding cures for diseases that are currently untreatable.”

The consortium includes: Cedars-Sinai Medical Center; Johns Hopkins University School of Medicine in Baltimore; University of California, Irvine; University of Wisconsin School of Medicine; Massachusetts General Hospital; Harvard Medical School; University of California, San Francisco; Cardiff University; Universita degli Studi di Milano; and the CHDI Foundation.

Funding for the research came from an American Recovery and Reinvestment Act grant from the NIH’s National Institute of Neurological Disorders and Stroke (NINDS Recovery Act grant number: RC2-NS069422 ), a grant from the CHDI Foundation, Inc. and CIRM.

Nicole White | Cedars-Sinai News
Further information:
http://www.cshs.org

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

A new dead zone in the Indian Ocean could impact future marine nutrient balance

06.12.2016 | Earth Sciences

Significantly more productivity in USP lasers

06.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>